Reacta Healthcare Ltd, a UK-based developer of food allergy diagnostic products, announced on Thursday the appointment of Richard Nagle as chair of its board of directors.
Nagle has more than 30 years of experience in the pharmaceutical, biotechnology and medical technology sectors, including in immunology. Reacta says that he has founded and led multiple companies, raised tens of millions of dollars of funding, achieved several successful exits and delivered operational transformations as companies grow.
Among his senior leadership positions, Nagle was a strategic advisor and CEO at Immune Regulation (now Revolo Biotherapeutics and formerly Peptinnovate). In addition to his role as chair of Reacta Healthcare, he is a part-time executive director at SASPiPhi, a company developing precision antimicrobials.
Professor Ashley Woodcock, a co-founder of Reacta Healthcare and chair since inception, remains with the company in a non-executive director role.
Reacta Healthcare names new chair of board
Lario Therapeutics awarded USD2.4m in grants for neuronal calcium channel research
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
Cedar Health Research opens new embedded research site within Texas Native Health
Merck and Mayo Clinic launch AI-driven drug discovery collaboration